Here, by Cox modeling, we develop IRS—which combines TMB with CD274, PDCD1, ADAM12 and TOP2A quantitative expression—to predict pembrolizumab rwPFS (648 patients; 26 tumor types; IRS-High or -Low groups). The gene discussed is IARS1; the disease is neoplasm.